37 results about "Synovial sarcoma" patented technology

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit, insulin-like growth factor-I receptor, antagonize the effects of IGF-I, IGF-II and serum on the growth and survival of tumor cells, and which are substantially devoid of agonist activity. Said antibodies and fragments thereof may be used, optionally in conjunction with other therapeutic agents, in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma, prostate cancer and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit, insulin-like growth factor-I receptor, antagonize the effects of IGF-I, IGF-II and serum on the growth and survival of tumor cells, and which are substantially devoid of agonist activity. Said antibodies and fragments thereof may be used, optionally in conjunction with other therapeutic agents, in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma, prostate cancer and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit A class of Eph receptors, antagonize the effects of growth factors on the growth and survival of tumor cells, and which have minimal agonistic activity or are preferentially devoid of agonist activity. Said antibodies and fragments thereof may be used in the treatment of tumors that express elevated levels of A class of Eph receptors, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of A class of Eph receptors. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the A class of Eph receptors.

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.

A therapeutic agent for soft tissue sarcoma (particularly synovial sarcoma), contains a histone deacetylase inhibitor (particularly a compound of formula I) as an active ingredient

Methods of detecting synovial sarcoma using differentially expressed genes are disclosed. Also disclosed are methods of identifying agents for treating synovial sarcoma. Further, a method for treating or preventing a disease that is associated with Frizzled homologue 10 (FZD10) in a subject is provided.

The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for synovial sarcoma X Breakpoint (SSX)-2. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.

The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for synovial sarcoma X Breakpoint (SSX)-2. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.

Methods of detecting synovial sarcoma using differentially expressed genes are disclosed. Also disclosed are methods of identifying agents for treating synovial sarcoma. Further, a method for treating or preventing a disease that is associated with Frizzled homologue 10 (FZD10) in a subject is provided.

Methods and compositions are provided for treating human synovial sarcoma (SS). Also provided are screens to identify therapeutics for the treatment of synovial sarcoma. These methods, compositions, and screens are based on the discovery that promoting the assembly of wild type BAF (also called mSWI / SNF) complexes in SS cells by increasing levels of wild type SS18 and / or decreasing levels of SS18-SSX fusion protein leads to the cessation of proliferation of malignant cells in synovial sarcoma.

The invention provides a synovial sarcoma cell line hss-005R, which is preserved in the China Center for Type Culture Collection (CCTCC) with the preservation number of CCTCC NO. C201911. The invention further provides an offspring cell line of the synovial sarcoma cell line hss-005R. A new human synovial sarcoma cell line is established, which is stable in character and can be stably passed for multiple generations. Under the premise of retaining main clinical biological characteristics, the established human synovial sarcoma cell line has the characteristics of high tumor formation rate, short incubation period, good uniformity and the like, enriches a synovial sarcoma cell bank, and can successfully establish a synovial sarcoma animal model, wherein the established animal model can be used for fundamental research and drug screening, so as to provide powerful scientific research data for the research developed on the basis of Chinese population genetic background, and provide new test material for test on sensibility and tolerance of a clinical anti-cancer drug of a new drug preclinical study in vivo experiment.

The invention provides a T cell receptor (TCR) capable of being specifically bound with oligopeptide KASEKIFYV derived from an SSX2 (synovial sarcoma X breakpoint 2) antigen. The antigen oligopeptideKASEKIFYV and HLA (human leukocyte antigen) A0201 can form a compound and be present to a cell surface. The invention further provides a nucleic acid molecule for encoding the TCR, and a carrier comprising the nucleic acid molecule. In addition, the invention further provides a cell for conducting the TCR.

The invention provides a construction method and application of a synovial sarcoma heterogenous transplanting mouse model. The method comprises the steps of firstly, collecting a synovial sarcoma patient tumor tissue block, and performing heterogenous in-situ transplanting of the fresh patient tumor tissue block into an immune deficiency mouse body under the sterile condition, wherein heterogenousin-situ planting includes the steps of selecting a 2-6-week old immune deficiency mouse, the mouse is consistent with the patient in gender, the collected fresh patient tumor tissue block is soaked with a sterile incubation solution containing fetal calf serum, the mouse is fixed after anesthesia, the patient tumor tissue block is planted into the joint capsule of the mouse, an incision is sewn,and the mouse is bred so that a tumor in the joint capsule can grow. Compared with subcutaneous modeling, the in-situ modeling condition is more real, the screened medicine scheme can be better used for the patient, and on the basis of the in-situ modeling theory, tumor metastasis is more likely to happen compared with subcutaneous modeling.

Methods and compositions for treating cancers such as pancreatic cancer and synovial sarcoma are disclosed. Compounds comprising a sigma-2 receptor-binding moiety and a ferroptosis-inducing moiety are described. At least one described molecular species exhibits an IC50 value below 5 μM against human pancreatic cancer cells in vitro. Administration of this species promoted shrinkage of pancreatic cancer tumors in a murine model system in vivo, and led to 100% survival of experimental animals over a time course in which control therapies provided only 30% or 40% survival. Methods of synthesis of molecular species are also disclosed.

The invention relates to a preparation method of a synovial sarcoma cell line hSS-005R. The synovial sarcoma cell line is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO:C201911; the preparation method comprises primary culture and subculture. The new human synovial sarcoma cell line is established, has stable properties and can achieve stable passage several times. The established human synovial sarcoma cell line has the advantages of a high tumor formation rate, a short incubation period, good homogeneity and the like on the premise of retaining main clinical biological characteristics, so that a synovial sarcoma cell bank is enriched, a synovial sarcoma animal model can be successfully prepared, the animal model can be used for basic research and drug screening, powerful scientific research data is provided for research based on the genetic background of Chinese population, and a new test material is also provided for testing the sensitivity and drug resistance of clinical anticancer drugs during in-vivo research experiments before clinical use of new drugs.

Antibodies, humanized antibodies, resurfaced antibodies antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit, insulin-like growth factor-I receptor, antagonize the effects of IGF-I, IGF-II and serum on the growth and survival of tumor cells, and which are substantially devoid of agonist activity. The antibodies and fragments thereof may be used, optionally in conjunction with other therapeutic agents, in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma, prostate cancer and pancreatic cancer and the derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.

The invention provides a method for constructing a synovial sarcoma xenograft mouse model with sound immunity. The method comprises the steps of culture of a P0 generation, wherein firstly, fresh tumor tissue masses of a patient with a synovial sarcoma are collected and then transplanted into the body of a mouse with immune deficiency under a sterile condition; a mouse with normal immunity is subjected to ciclosporin pretreatment; culture of Px generations, wherein tumor tissue masses growing in the body of a mouse of any generation from P0-P<x-1> are taken to be inoculated into the body of amouse subjected to the ciclosporin pretreatment to form a Px-generation mouse; culture of Py generations, wherein synovial sarcoma tumor tissue masses growing in the body of a mouse of any generationfrom Px-P<y-1> are taken to be inoculated into the body of the mouse with the normal immunity until tumor tissue grows in the body of the mouse with the normal immunity, and the culture of the Py generations is completed. The method solves the problem that a traditional PDX model has no immune system, provides an in-vivo model for a tumor immunotherapy, and broadens the application range of the PDX model.

Use of muscle-enriched / specific microRNAs for the treatment of sarcomas, as for example rhabdomyosarcomas, synovial sarcoma, alveolar soft part sarcoma, liposarcoma, and osteosarcoma, wherein the microRNAs are able to stop the development of neoplastic cells and to force the neoplastic cells to differentiate into terminally differentiated muscle cells.

Methods and compositions are provided for treating human synovial sarcoma (SS). Also provided are screens to identify therapeutics for the treatment of synovial sarcoma. These methods, compositions, and screens are based on the discovery that promoting the assembly of wild type BAF (also called mSWI / SNF) complexes in SS cells by increasing levels of wild type SS18 and / or decreasing levels of SS18-SSX fusion protein leads to the cessation of proliferation of malignant cells in synovial sarcoma.

Methods useful in the treatment of synovial sarcoma are provided. The methods comprise administering to a subject suffering from synovial sarcoma a compound as disclosed herein. Also provided are novel compounds having therapeutic effects on subjects suffering from synovial sarcoma and pharmaceutical compositions comprising the compounds. The compounds were identified by screening for agents that promote the assembly of wild-type BAF (also called mSWI / SNF) complexes in modified SS cells.

The invention provides a method for constructing an immune healthy synovial sarcoma xenograft mouse model; the method comprises cultivating a generation P0, to be specific, resuscitating a tumor tissue block of a synovial sarcoma patient stored in a liquid nitrogen environment, then transplanting the tumor tissue block into an immunodeficient mouse under a sterile condition, and pretreating a micewith normal immunity by cyclosporine; culturing a generation Px, to be specific, inoculating the tumor tissue block, grown in a mouse from any of the generations P0 to Px, into the mouse pretreated with cyclosporine to form a generation Px mouse; and culturing a generation Py, to be specific, inoculating a synovial sarcoma tumor tissue block, grown in a mouse from any of the generations Px to Py-1, into the mouse with normal immunity until tumor tissues grow in the mouse, so that culturing of the generation Py is completed. The invention solves the problem that the traditional PDX (patient-derived xenograft) model has no immune system, provides an in-vivo model for the research on tumor immunotherapy, and widens the application range of the PDX model.

The present invention relates to Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR) inhibitors for use in methods of treating BAF-complex deficient cancer. The present invention further provides methods for identifying ATR inhibitors for use in the treatment of BAF complex gene mutant or deficient cancers. Medical uses and methods relating to the treatment of synovial sarcoma using ATR inhibitors are also provided.

The invention provides a method for constructing an immune-sound synovial sarcoma xenograft mouse model, which includes the cultivation of the P0 generation: first resuscitating the tumor tissue block of a synovial sarcoma patient stored in a liquid nitrogen environment, and then under aseptic conditions It was transplanted into immunodeficient mice; normal immune mice were pretreated with cyclosporine; culture of Px generation: the tumor tissue pieces grown in any generation of mice from P0 to Px‑1 generation were inoculated into the above-mentioned From the mice pretreated with cyclosporine, the Px generation mice were formed; the cultivation of the Py generation: take the synovial sarcoma tumor tissue pieces grown in any generation of mice from the Px generation to the Py-1 generation above and inoculate them into normal immune cells. In the mouse body, until the tumor tissue grows in the body, the culture of the Py generation is completed. The invention improves the problem that the traditional PDX model has no immune system, provides an in vivo model for the research of tumor immunotherapy, and broadens the application range of the PDX model.

The present invention relates to a method for increasing plant yield by modulating expression in a plant of a nucleic acid encoding a synovial sarcoma translocation (SYT) polypeptide or a homologue thereof. One such method involves introducing a SYT nucleic acid or variant thereof into a plant. The present invention also relates to transgenic plants into which a SYT nucleic acid or a variant thereof has been introduced, said plants having an increased yield relative to corresponding wild-type plants. The invention also relates to constructs useful in the methods of the invention.

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.

A method for inhibiting or reducing an expression of FZD10 gene is provided. Also, a method for treating and / or preventing FZD10-associated disease in a subject is provided. Further provided is a pharmaceutical composition comprising an double-stranded RNA molecule for FZD10 or an expression vector capable of expressing a double-stranded RNA molecule for FZD10.

The invention relates to a preparation method of a synovial sarcoma cell line hSS-005R. The synovial sarcoma cell line is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO:C201911; the preparation method comprises primary culture and subculture. The new human synovial sarcoma cell line is established, has stable properties and can achieve stable passage several times. The established human synovial sarcoma cell line has the advantages of a high tumor formation rate, a short incubation period, good homogeneity and the like on the premise of retaining main clinical biological characteristics, so that a synovial sarcoma cell bank is enriched, a synovial sarcoma animal model can be successfully prepared, the animal model can be used for basic research and drug screening, powerful scientific research data is provided for research based on the genetic background of Chinese population, and a new test material is also provided for testing the sensitivity and drug resistance of clinical anticancer drugs during in-vivo research experiments before clinical use of new drugs.